SIGA - 2000% pump
In March 2022, the stock of SIGA Technologies saw a significant increase due to growing concerns about the monkeypox outbreak. The primary driver of this growth was the World Health Organization (WHO) declaring the monkeypox outbreak a global health emergency. This attracted investors' attention to the company, as its main product, the antiviral drug Tecovirimat (TPOXX), was developed to treat smallpox and has proven effective against monkeypox.
Publicaciones relacionadas
Exención de responsabilidad
La información y las publicaciones que ofrecemos, no implican ni constituyen un asesoramiento financiero, ni de inversión, trading o cualquier otro tipo de consejo o recomendación emitida o respaldada por TradingView. Puede obtener información adicional en las Condiciones de uso.